CO MYCOPHENOLATE TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
22-10-2013
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
MYCOPHENOLATE MOFETIL
Tilgængelig fra:
COBALT PHARMACEUTICALS COMPANY
ATC-kode:
L04AA06
INN (International Name):
MYCOPHENOLIC ACID
Dosering:
500MG
Lægemiddelform:
TABLET
Sammensætning:
MYCOPHENOLATE MOFETIL 500MG
Indgivelsesvej:
ORAL
Enheder i pakken:
50/100
Recept type:
Prescription
Terapeutisk område:
IMMUNOSUPPRESSIVE AGENTS
Produkt oversigt:
Active ingredient group (AIG) number: 0128158002; AHFS:
Autorisation status:
CANCELLED POST MARKET
Autorisation dato:
2018-05-07
Produktets egenskaber
_ _
_ _
_Page 1 of 55_
PRODUCT MONOGRAPH
PR
_CO_ MYCOPHENOLATE
Mycophenolate Mofetil Tablets USP
500 mg
Immunosuppressive Agent
Cobalt Pharmaceuticals Company
6500 Kitimat Road
Mississauga, Ontario
L5N 2B8
SUBMISSION CONTROL NO: 168316
Date of Revision:
October 16, 2013
_ _
_ _
_Page 2 of 55_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND ADMINISTRATION
.............................................................................
18
OVERDOSAGE
...............................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 20
STORAGE AND STABILITY
.........................................................................................
27
SPECIAL HANDLING INSTRUCTIONS
......................................................................
27
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 27
PART II: SCIENTIFIC INFORMATION
..............................................................................
28
PHARMACEUTICAL INFORMATION
.........................................................................
28
CLINICAL TRIALS
.........................................................................................................
29
DETAILED PHARMACOLOGY
.............................................................................
Læs hele dokumentet
